From: Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review
Reference | Type of study | Model/causes | Type of ECMO | MSC Sources | Patient/animal enrolled | Transplantation | Regimen | Main findings |
---|---|---|---|---|---|---|---|---|
Lin et al. [75] | Clinical study | Adenovirus pneumonia | VV-ECMO and VA-ECMO | BM-MSCs | 1 | i.t | 6.25 × 106cells/kg, single dose | Respiratory and lung condition improved |
Kaushal et al. [45] | Clinical study | COVID-19 | VV-ECMO | BM-MSCs | 40(9/31) | i.v | 2–3 doses | ↓Mortality,COVID-19 IgG Spike protein, the SOFA score, VEGF-A, IL-12-p70 ↑PaO2/FiO2 |
Simonson et al. [43] | Clinical study | A H1N1 | VV-ECMO; VA-ECMO | BM-MSCs | 2 | i.v | 2 × 106 cells/kg, Single dose | oxygenation and pulmonary compliance improved ↓ IL-6,IL-8,IFN-γ ↑Granulocyte macrophage colony-stimulating factor levels, surfactant protein B |
Jungebluth et al. [76] | Clinical study | Burn | VV-ECMO and VA-ECMO | PBMCs and EPO | 1 | i.t | (300 ± 50) × 106 PBMCs, on ECMO days 9, 10, 16, 21 and 23, total 5 dose and 30,000 IU EPO every other day, from ECMO day 9 to ECMO day 20, three times per day, total 18 doses | Further regression of inflammation in bronchoscopy images ↓WBC ↑CD14+,CD83−, miR-449a, b, c and miR-34a |
Liu et al. [47] | Clinical study | Pneumocystis carinii pneumonia | VV-ECMO | UCB | 1 | i.t | nucleated cells:0.77 × 106cells/kg live CD34 cells: 0.25 × 105cells/kg, single dose | Lung lesions and ECMO condition improved ↑CD16 + ,CD56 + ↓IL-α,IL-6,IL-8,IL-10,IL-1β, PCT |
Tao et al. [74] | Clinical study | COVID-19 | Unknown | UCB-MSCs | 1 | i.t | 1.5 × 106cells/kg, Every 48 h, total 5dose | PaO2/FiO2 ratio maintained stable ↓Blood creatinine, urea nitrogen ↑Pulmonary static compliance |
Millar et al. [42] | Animal study | Border Leicester Cross ewes, oleic acid i.v. and E. coli LPS i.t | VV-ECMO | iPSC-derived hMSCs | 14(7/7) | i.t | After 1 h of VV-ECMO, 3 × 108iPSC-derived hMSCs, Single dose | the membrane oxygenator function is impaired ↓Lung inflammation, lymphocyte count,IL-8, the depth and severity of shock ↑Pulmonary arterial thromboses |
Kocyildirim et al.41 | Animal study | Sheep, E. coli endotoxin | VV-ECMO | MAPC | 11(5/3/3) | i.t | After 1.5 h of the infusion of E. coli endotoxin, followed by VV-ECMO support; 40 million cells; Single dose | ↑Pulmonary artery pressure, neutrophils counts Less inflammatory and hemorrhagic change in lungs |